A detailed history of Royal Bank Of Canada transactions in Vaxart, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 280 shares of VXRT stock, worth $162. This represents 0.0% of its overall portfolio holdings.

Number of Shares
280
Previous 468 40.17%
Holding current value
$162
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.58 - $0.99 $109 - $186
-188 Reduced 40.17%
280 $0
Q2 2024

Aug 14, 2024

BUY
$0.53 - $1.3 $14 - $35
27 Added 6.12%
468 $0
Q1 2024

Nov 05, 2024

SELL
$0.56 - $1.41 $15 - $38
-27 Reduced 5.77%
441 $0
Q1 2024

May 15, 2024

SELL
$0.56 - $1.41 $2,735 - $6,886
-4,884 Reduced 91.72%
441 $0
Q4 2023

Feb 14, 2024

BUY
$0.57 - $0.85 $1,165 - $1,738
2,045 Added 62.35%
5,325 $3,000
Q3 2023

Nov 14, 2023

SELL
$0.69 - $0.85 $3,415 - $4,207
-4,950 Reduced 60.15%
3,280 $2,000
Q2 2023

Aug 14, 2023

SELL
$0.6 - $1.41 $1,465 - $3,444
-2,443 Reduced 22.89%
8,230 $6,000
Q1 2023

May 15, 2023

SELL
$0.71 - $1.25 $8,336 - $14,677
-11,742 Reduced 52.38%
10,673 $8,000
Q4 2022

Feb 14, 2023

BUY
$0.75 - $2.24 $9,681 - $28,916
12,909 Added 135.8%
22,415 $21,000
Q3 2022

Nov 14, 2022

SELL
$2.09 - $4.5 $2,909 - $6,264
-1,392 Reduced 12.77%
9,506 $20,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $5.28 $18,416 - $36,014
-6,821 Reduced 38.5%
10,898 $38,000
Q1 2022

May 16, 2022

SELL
$4.29 - $6.64 $85,379 - $132,149
-19,902 Reduced 52.9%
17,719 $89,000
Q4 2021

Feb 14, 2022

BUY
$5.77 - $7.96 $91,846 - $126,707
15,918 Added 73.34%
37,621 $236,000
Q3 2021

Nov 15, 2021

SELL
$6.67 - $9.8 $11,185 - $16,434
-1,677 Reduced 7.17%
21,703 $173,000
Q2 2021

Aug 16, 2021

BUY
$5.06 - $10.78 $118,302 - $252,036
23,380 New
23,380 $175,000

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $73.4M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.